title: Elevation of {beta}-amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment.
abstract: OBJECTIVE
  To develop a blood-based test for screening populations at risk for Alzheimer disease.
  
  
  METHODS
  Case-control study. Subjects A total of 180 patients with mild cognitive impairment (MCI) and 105 age-matched, cognitively normal controls.
  
  
  METHODS
  The titer of beta-amyloid 1-42 autoantibodies in the plasma was obtained at the time of diagnosis and evaluated by enzyme-linked immunosorbent assay before and after dissociation of the antigen-antibody complexes. A total of 107 patients with MCI were followed up for 36 months; 70 of the 107 cases progressed to Alzheimer disease.
  
  
  RESULTS
  The average level of beta-amyloid 1-42 plasma autoantibodies in patients with MCI that progressed to Alzheimer disease, but not that of the stable cases, was significantly higher than in cognitively normal controls (P < .001).
  
  
  CONCLUSIONS
  The results suggest that the plasma beta-amyloid 1-42 autoantibodies parallel beta-amyloid 42 deposition in the brain, which is known to precede by several years the clinical onset of Alzheimer disease. The evaluation of beta-amyloid 1-42 autoantibodies after dissociation of the complexes is a simple and inexpensive method that can be used to predict the occurrence of Alzheimer disease.
authors.affiliation: Department of Internal Medicine and Medical Specialties, University of Genoa, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Storace
authors.forename: Sergio
authors.initials: S
authors.lastname: Cammarata
authors.forename: Roberta
authors.initials: R
authors.lastname: Borghi
authors.forename: Roberta
authors.initials: R
authors.lastname: Sanguineti
authors.forename: Luca
authors.initials: L
authors.lastname: Giliberto
authors.forename: Alessandra
authors.initials: A
authors.lastname: Piccini
authors.forename: Valeria
authors.initials: V
authors.lastname: Pollero
authors.forename: Cristina
authors.initials: C
authors.lastname: Novello
authors.forename: Carlo
authors.initials: C
authors.lastname: Caltagirone
authors.forename: Mark A
authors.initials: MA
authors.lastname: Smith
authors.forename: Paola
authors.initials: P
authors.lastname: Bossù
authors.forename: George
authors.initials: G
authors.lastname: Perry
authors.forename: Patrizio
authors.initials: P
authors.lastname: Odetti
authors.forename: Massimo
authors.initials: M
authors.lastname: Tabaton
mesh_terms: D000647:Amnesia / Q000097:blood / Q000150:complications; D016229:Amyloid beta-Peptides / Q000276:immunology*; D053327:Apolipoprotein E4 / Q000235:genetics; D016022:Case-Control Studies; D003072:Cognition Disorders / Q000097:blood* / Q000209:etiology / Q000235:genetics / Q000276:immunology*; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D010446:Peptide Fragments / Q000276:immunology*; D011336:Probability
chemical_list: D016229:Amyloid beta-Peptides; D053327:Apolipoprotein E4; D007074:Immunoglobulin G; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)